
Clinical TrialNov 13, 2026, 10:16 AM
Valneva: Positive Shigella Vaccine Trial Results & 5-Year Chikungunya Vaccine Data
AI Summary
Valneva SE announced positive results from two Phase 2 trials for its Shigella vaccine candidate S4V2, with the CHIM trial meeting its primary endpoint and the infant trial demonstrating favorable immunogenicity and safety. Additionally, five-year follow-up data for its chikungunya vaccine IXCHIQ® showed 94% of participants maintained seroresponse, with comparable antibody persistence across age groups. Valneva is assessing the S4V2 data to plan further development, while the IXCHIQ® data reinforce its potential for long-term protection.
Key Highlights
- Valneva's Shigella vaccine candidate S4V2 met its primary endpoint in a Phase 2 CHIM trial, showing a statistically significant reduction in shigellosis incidence.
- Phase 2 infant trial showed S4V2 induced immune responses for all four targeted Shigella serotypes with favorable safety and tolerability.
- Five-year data for Valneva's chikungunya vaccine IXCHIQ® show 94% of participants maintained seroresponse.
- Antibody persistence in older adults (65+) for IXCHIQ® was comparable to younger adults.
- Valneva is evaluating the complete dataset for S4V2 to determine the next steps for development.
- IXCHIQ®'s five-year data further support its potential for long-term protection after a single vaccination.
- The chikungunya vaccine IXCHIQ® is being studied for long-term durability of immune responses for up to ten years.
- A pilot vaccination strategy for IXCHIQ® in Brazil vaccinated nearly 80,000 adults.
Price Impact
More from VALN